Cargando…
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
INTRODUCTION: Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and exp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115781/ https://www.ncbi.nlm.nih.gov/pubmed/35294307 http://dx.doi.org/10.1080/13543784.2022.2054325 |
_version_ | 1784709990716538880 |
---|---|
author | Garrido-Mesa, Jose Adams, Kate Galvez, Julio Garrido-Mesa, Natividad |
author_facet | Garrido-Mesa, Jose Adams, Kate Galvez, Julio Garrido-Mesa, Natividad |
author_sort | Garrido-Mesa, Jose |
collection | PubMed |
description | INTRODUCTION: Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and experimental reports suggest a direct antiviral activity against SARS-CoV2. Furthermore, a few clinical reports indicate their potential in COVID-19 patients. In addition to the scarcity and limitations of the scientific evidence, the effectiveness of tetracyclines in experimental ARDS has been proven extensively, counteracting the overt inflammatory reaction and fibrosis sequelae due to a synergic combination of pharmacological activities. AREAS COVERED: This paper discusses the scientific evidence behind the application of tetracyclines for ARDS/COVID-19. EXPERT OPINION: The benefits of their multi-target pharmacology and their safety profile overcome the limitations, such as antibiotic activity and low commercial interest. Immunomodulatory tetracyclines and novel chemically modified non-antibiotic tetracyclines have therapeutic potential. Further drug repurposing studies in ARDS and severe COVID-19 are necessary. |
format | Online Article Text |
id | pubmed-9115781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91157812022-05-18 Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications Garrido-Mesa, Jose Adams, Kate Galvez, Julio Garrido-Mesa, Natividad Expert Opin Investig Drugs Review INTRODUCTION: Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and experimental reports suggest a direct antiviral activity against SARS-CoV2. Furthermore, a few clinical reports indicate their potential in COVID-19 patients. In addition to the scarcity and limitations of the scientific evidence, the effectiveness of tetracyclines in experimental ARDS has been proven extensively, counteracting the overt inflammatory reaction and fibrosis sequelae due to a synergic combination of pharmacological activities. AREAS COVERED: This paper discusses the scientific evidence behind the application of tetracyclines for ARDS/COVID-19. EXPERT OPINION: The benefits of their multi-target pharmacology and their safety profile overcome the limitations, such as antibiotic activity and low commercial interest. Immunomodulatory tetracyclines and novel chemically modified non-antibiotic tetracyclines have therapeutic potential. Further drug repurposing studies in ARDS and severe COVID-19 are necessary. Taylor & Francis 2022-03-23 /pmc/articles/PMC9115781/ /pubmed/35294307 http://dx.doi.org/10.1080/13543784.2022.2054325 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Review Garrido-Mesa, Jose Adams, Kate Galvez, Julio Garrido-Mesa, Natividad Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications |
title | Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications |
title_full | Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications |
title_fullStr | Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications |
title_full_unstemmed | Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications |
title_short | Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications |
title_sort | repurposing tetracyclines for acute respiratory distress syndrome (ards) and severe covid-19: a critical discussion of recent publications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115781/ https://www.ncbi.nlm.nih.gov/pubmed/35294307 http://dx.doi.org/10.1080/13543784.2022.2054325 |
work_keys_str_mv | AT garridomesajose repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications AT adamskate repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications AT galvezjulio repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications AT garridomesanatividad repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications |